Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota And Daiichi Sankyo
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese approval is anticipated in 2010, but Biota is seeking an ex-Japan development partner to replicate Asian studies and seek U.S. and European approvals.
You may also be interested in...
Daiichi Sankyo Exercises Option With Aussie Biotech Biota For Second-Gen Flu Drug
PERTH, Australia - Daiichi Sankyo has exercised its option to manufacture and market in Japan its second-generation influenza long-acting neuraminidase inhibitor CS-8958, co-owned with Autralian biotech Biota. The agreement is contingent upon successful completion of pivotal Phase III trials and approval, Biota announced March 30
Daiichi Sankyo And Aussie Biotech Biota Begin Phase III Asian Trials For Second-Generation Flu Drug
PERTH, Australia - Daiichi Sankyo and Australian partner Biota have begun pivotal Phase III trials for anti-influenza drug CS-8958 in Japan, Taiwan, Hong Kong and Korea
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.